NCT05804526View on ClinicalTrials.gov

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumours
Interventions
DRUG

RC88

1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks

DRUG

Sintilimab Injection

Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY